Correlates of Angiographic Changes and Coronary Events

Sponsor
University of Southern California (Other)
Overall Status
Completed
CT.gov ID
NCT00005433
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
188
12

Study Details

Study Description

Brief Summary

To examine the appropriateness of angiographic and ultrasound endpoints as predictors of subsequent clinical coronary events. Follow-up data from the Cholesterol Lowering in Atherosclerosis Study (CLAS) were used.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    BACKGROUND:

    A multitude of coronary angiographic trials have been conducted using various endpoint measures based on repeated coronary angiograms. Relative to coronary event trials, angiographic trials require both a smaller sample size and reduced trial length. While such trials have assumed that angiographic endpoints are valid surrogate measures for clinical coronary events, this assumption has not been completely tested. Although several coronary angiographic endpoints are available for trial outcomes, no single method has been uniformly accepted as optimal. Because of this, the utility and validity of coronary angiographic progression for predicting future clinical coronary events remains unsettled.

    The recent advent of carotid ultrasonography to assess arterial intima-media thickness (IMT) offers the exciting potential for a noninvasive measure of atherosclerosis. Because of its noninvasiveness, carotid IMTallows the extension of anti-atherosclerotic trials to both asymptomatic and frail subjects, for whom coronary angiography might be medically unethical. Because there is currently only limited support for the association of carotid IMT with clinical events or coronary atherosclerosis, the validity of carotid IMT as a potential surrogate for either endpoint has not been established.

    The Cholesterol Lowering Atherosclerosis Study (CLAS) was a coronary angiographic trial testing the efficacy of colestipol-niacin therapy in 188 nonsmoking, 40-59 year old men with previous coronary artery bypass graft surgery. Coronary artery atherosclerosis change was evaluated both by human consensus panel and by quantitative coronary angiography (QCA). In addition, B-mode ultrasounds of the common carotid artery was conducted every six months to provide measures of carotid IMT. Since the competion of the two-year CLAS study, subjects have been followed for up to 12 years. This long term follow-up of the CLAS cohort permits examination of the appropriateness of angiographic and ultrasound arterial endpoints as predictors of subsequent clinical coronary events. Angiographic and ultrasound (carotid IMT) endpoints also allow for testing of the associations between these various serial measures of atherosclerotic progression.

    The results of these analyses will provide important information on the validity of these measures, which are in current use as trial endpoints, as surrogates for clinical coronary events.

    DESIGN NARRATIVE:

    The study used angiographic and ultrasound carotid intima medial thickness endpoints for testing the associations between these various serial measures of atherosclerotic progression and subsequent coronary heart disease.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    188 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Correlates of Angiographic Changes and Coronary Events: The Cholesterol-Lowering Atherosclerosis Study (CLAS)
    Study Start Date :
    Apr 1, 1996
    Actual Primary Completion Date :
    Apr 1, 1997
    Actual Study Completion Date :
    Apr 1, 1997

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      40 Years to 100 Years
      Sexes Eligible for Study:
      Male
      Accepts Healthy Volunteers:
      No

      Male Nonsmoker Prior coronary artery bypass graft surgery

      Contacts and Locations

      Locations

      No locations specified.

      Sponsors and Collaborators

      • University of Southern California
      • National Heart, Lung, and Blood Institute (NHLBI)

      Investigators

      None specified.

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      Responsible Party:
      Wendy Mack, Professor, University of Southern California
      ClinicalTrials.gov Identifier:
      NCT00005433
      Other Study ID Numbers:
      • 4351
      • R03HL054532
      First Posted:
      May 26, 2000
      Last Update Posted:
      Apr 24, 2017
      Last Verified:
      Apr 1, 2017
      Individual Participant Data (IPD) Sharing Statement:
      No
      Plan to Share IPD:
      No
      Studies a U.S. FDA-regulated Drug Product:
      No
      Studies a U.S. FDA-regulated Device Product:
      No
      Additional relevant MeSH terms:

      Study Results

      No Results Posted as of Apr 24, 2017